PAD6: ASSESSMENT OF THE ECONOMIC AND HUMANISTIC OUTCOMES OF THE WEST VIRGINIA MEDICAID'S PRIOR AUTHORIZATION POLICY FOR NSAIDS  by Momani, A et al.
Abstracts 191
CONCLUSION: Using change scores responding to a
one-level improvement of PtGA or PhGA or using the av-
erage difference of change between any two levels im-
provement of PtGA or PhGA, the clinically meaningful
improvement for WOMAC pain, stiffness, physical func-
tioning, and total WOMAC scores were approximately
2, 1, 7, and 10, respectively.
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HRQoL measures are becoming important for evaluating
the effects of arthritis treatments. Interpreting changes in
HRQoL scores, however, has not been fully evaluated. 
OBJECTIVE: To determine the clinically meaningful im-
provement of HRQoL as measured by the SF-36 among
OA patients. 
METHODS: Data were obtained from three 12-week ran-
domized clinical trials among 3369 OA flare patients. The
SF-36 and Patient Global Assessment (PtGA) were admin-
istered to patients at baseline and week 12. PtGA was
measured on the following 1- to 5-point scale: very good,
good, fair, poor, or very poor. Change scores were com-
puted by subtracting patient’s baseline from week 12 fol-
low-up scores. Clinically meaningful improvement was es-
timated as the mean change score corresponding to a one-
level improvement in PtGA. A similar interpretation of
clinically meaningful changes was also performed using
physician-global assessment, pain, and functional-status. 
RESULTS: At week 12, the following patients experi-
enced improvements in their PtGA rating: one-level
(1158), two-levels (745), three or more levels (311),
which corresponded to standardized physical and mental
component scores (PCS & MCS) improvements of: one-
level (3.8 and 1.4), two-levels (8.3 and 2.7), and three or
more levels (10.4 and 4.2), respectively. The clinically
meaningful improvement based on PtGA among OA pa-
tients were approximately 3.8 and 1.4 for PCS and MCS,
respectively. The clinically meaningful changes for eight
SF-36 domains were 7.2 for physical function, 13.1 for
role physical, 11.6 for bodily pain, 2.1 for general health,
5.6 for vitality, 6.2 for social function, 7.7 for role emo-
tion, 2.7 for mental health. 
CONCLUSION: Clinically meaningful improvement var-
ies between SF-36 domains and summary scores among
OA patients. These results provide guidance in interpret-
ing HRQoL results and planning clinical trials.
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Given the widespread use of NSAIDs and its association
with gastric injury, the patterns and costs of gastric toxic-
ity are of interest. 
OBJECTIVE: The goal of this study was to describe the
prevalence of concomitant antiulcer medication with
NSAIDs. 
METHODS: We identified patients diagnosed with os-
teoarthritis (OA) (ICD-9 codes: 715, 721.0, 721.3,
721.9), rheumatoid arthritis (RA) (ICD-9 codes: 714.0,
714.1, 714.2, 714.9) or both (OA/RA) between 1992
and 1997 using a managed care claims database. Study
participants had at least 12 months of continuous health
coverage (including drug benefits). We examined initial
NSAID choice and the prevalence of concomitant gas-
trointestinal (GI) drug use (H2 antagonists [H2], proton
pump inhibitors [PPI], prostaglandins [PS]) during the
study period. 
RESULTS: Among NSAID users (n  40,350), ibuprofen
(28.6%) and naproxen (18.2%) were most likely to be
prescribed initially. Antiulcer medication use was more
prevalent in patients receiving NSAID therapy, appeared
to increase with age and vary by diagnosis: rates varied
from 19.1% (OA), 19.6% (RA), 34.3% (OA/RA) in pa-
tients aged 18–39 to 29.2%, 32.3%, and 40.0% in pa-
tients aged 70–79. Fifteen percent of patients had a con-
comitant GI prescription added to their therapy within
60 days after the first NSAID prescription. Most of the
anti-ulcerant use was H2 (76.9%), although PPI use
(10.7%) and PS use (12.4%) increased in latter years. 
CONCLUSIONS: We found that the prevalence of GI
therapy varied by age and diagnosis and that concomi-
tant GI medication use began soon after the initiation of
NSAID therapy.
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The West Virginia Medicaid’s (WVM) prior authoriza-
tion (PA) policy for NSAIDs is expected to produce sav-
ings to the WVM for two reasons: 1) NSAIDs are among
the most frequently utilized drugs in WVM, and 2) while
prices for NSAIDs vary substantially, most of the pre-
scribed NSAIDs are the expensive ones. However, a con-
cern arises whether the anticipated savings of policy im-
plementation may be offset by increased costs of
substitutable drugs and/or medical services. It is also im-
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portant to ensure that policy implementation did not
compromise patient outcomes. 
OBJECTIVES: The goals of this study were: 1) to assess
the net economic impact of PA for NSAIDs on WVM ex-
penditures, and 2) to determine the impact of the policy
on patients’ health-related quality of life (HRQoL). 
METHODS: The study was conducted in two phases. In
phase I, a quasi-experimental design was used to analyze
retrospective utilization data of recipients with continuous
Medicaid eligibility over the period of 18 months prior to
and 18 months after implementation, who were diagnosed
with rheumatoid arthritis, osteoarthritis, spondylitis, or
any other chronic pain syndrome. Segmented regression
analysis was used to model the impact of policy on WVM
expenditures. In phase II, patients who were newly diag-
nosed with any of the above-mentioned disorders, and for
whom a request for PA was received, were identified and
classified into two groups. Group I consisted of patients
who were approved a branded NSAID. Group II consisted
of patients who were denied a branded NSAID and
switched to a generic product. HRQoL was measured at
the time the patient was identified and two months later
using the Arthritis Impact Measurement Scales (AIMS).
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New therapies are available to manage rheumatoid arthri-
tis (RA) patients who fail currently available DMARD
therapies. Data on patterns of DMARD use will be useful
in evaluating new therapies. 
OBJECTIVE: Identify patterns of initial DMARD ther-
apy in RA patients. 
METHODS: We used claims data from an MCO to iden-
tify RA patients who 1) were 18 years of age, 2) were
prescribed a DMARD for 2 consecutive months between
July 1993 and February 1998, 3) had a diagnosis of RA
during 6 months prior to DMARD therapy, and 4) had 6
months of enrollment before initial DMARD therapy.
Among patients using alternative therapies, we compared
patient characteristics, duration of therapy and changes
in initial therapy. 
RESULTS: 564 patients met the inclusion criteria. Mean
age was 51 years; 60% were female; and 78% received
their initial prescription from a rheumatologist. Median
duration of initial therapy was 16 months for methotrex-
ate (n  196), 11 months for hydroxychloroquine (n 
260), 5 months for sulfasalazine (n  51), and 5 months
for other therapies (n  57). For the two most commonly
used DMARDS, hydroxychloroquine patients were sig-
nificantly more likely (adjusted odds ratio 1.44, p 
0.004) than methotrexate patients to discontinue all
DMARD therapy, switch to an alternative DMARD, or
begin taking one or more additional DMARDS.
CONCLUSIONS: Many RA patients change initial
DMARD therapy within 1 year, suggesting a potential
role for new therapies directed toward patients who fail
currently available first-line drugs.
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The Health Assessment Questionnaire Disability Index
(HAQ) has been proven to be a valid and reliable mea-
sure of daily living ability of arthritis patients. 
OBJECTIVE: To establish the clinically meaningful im-
provements of the HAQ and its domain scores among
RA patients. 
METHODS: Data were obtained from two 12-week ran-
domized clinical trials among 2252 RA flare patients.
The HAQ, Patient and Physician Global Assessments
(PtGA & PhGA) were administered to patients at base-
line and week 12. HAQ is a 20-item instrument that con-
tains eight categories of daily living activities. A compos-
ite score is calculated. PtGA & PhGA were measured on
the following 1- to 5-point scale: very good, good, fair,
poor, or very poor. Change scores were computed by
subtracting patients’ baseline from week 12 follow-up
scores. Responsiveness was estimated as the mean change
score corresponding to each level of improvement in
PtGA or PhGA.
RESULTS AND CONCLUSIONS: At week 12, the num-
ber of patients experiencing improvements in PtGA and
PhGA were: 783 and 796 for one-level, 387 and 388 for
two-levels, and 87 and 85 for three or more levels. The av-
erage improvement in HAQ disability index among pa-
tients experiencing one, two, or three or more levels were
0.25, 0.47, 0.76 for PtGA and 0.26, 0.46, and 0.64 for
PhGA. Using the change score corresponding to a one-level
improvement or using the average difference of change be-
tween any two levels of improvement of PtGA or PhGA, the
clinically meaningful improvement score ranged from 0.21
to 0.26. Using similar methods, the clinically meaningful
improvement scores for the following eight categories of
daily living were: dressing (0.29), eating (0.22), arising
(0.35), walking (0.24), hygiene (0.15), reach (0.21), grip
(0.24), and activities (0.28), respectively.
